2.1
Faricimab (Vabysmo, Roche) is indicated for 'the treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)'.
2 Information about faricimab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for faricimab.
Price
2.3
The list price of faricimab is £857 for 1 vial of 120 mg per 1 ml solution for injection (excluding VAT; BNF online accessed May 2024)
2.4
The company has a commercial arrangement. This makes faricimab available to the NHS with a discount. The size of the discount is commercial in confidence.